Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

My own bio-imprint as asset for competitive advantage

Periodic Reporting for period 1 - MYBIOASSET (My own bio-imprint as asset for competitive advantage)

Reporting period: 2015-12-01 to 2016-05-31

LEV2050 has developed and tested MYBIOASSETS, a method, procedure and technology to genetically select, preserve and reproduce indigenous yeasts, from different strains and genders. With this technology, wineries can create their own, unique wines with special characteristics provided by their own yeasts, selected from their vineyards, and reproduce those special flavours year after year making a difference among their competitors. MYBIOASSETS has been tested in several wineries in Spain with excellent results. The tailored engineered bioreactors designed by LEV2050 will help wineries to reproduce year after year the selected yeasts maintaining the highest level of quality.
"""The feasibility study has been carried out during 2016 and covers nex sections: MARKET STUDY AND INVOLVEMENT OF KEY STAKEHOLDERS: - Market features
- Value chain
- Market segments
- Opportunity
- Competition
- Regulation
- Commercialisation
- Risks
- Time to market FREEDOM TO OPERATE, VALUE PROPOSITION AND BUSINESS MODEL - Product/service
- Differentiation
- IPR
- Prospective
- Business model COST, REVENUES AND FUNDING SCHEME""
"
In comparison to competition products, MYBIOASSETS has a wider potential of differenciation. Instead of use commercial yeasts present in the market, each winery has the opportunity to select those yeasts present in their vineyards that provide wines with the most desirable organoleptic qualities. This differenciation allows wineries to make a difference in the market, improving sales expectations. With the help of tailored bioreactors, yeast cost per campaign will be affordable for wineries, independently from their size.
lev2050-2.png
lev2050-1.png